title: Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
authors: Department of Urology, University Hospital Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center, Hamburg, Germany.
authors: Andreas
authors: A
authors: Becker
authors: Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
authors: Christian
authors: C
authors: Eichelberg
authors: Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montreal Health Centre, Montreal, Quebec, Canada.
authors: Maxine
authors: M
authors: Sun
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D016898:Interferon-alpha